ADReCS

Cerebellar degeneration associated with a remote neoplasm. Clinical manifestations include progressive limb and GAIT ATAXIA; DYSARTHRIA; and NYSTAGMUS, PATHOLOGIC. The histologic type of the associated neoplasm is usually carcinoma or lymphoma. Pathologically the cerebellar cortex and subcortical nuclei demonstrate diffuse degenerative changes. Anti-Purkinje cell antibodies (anti-Yo) are found in the serum of approximately 50% of affected individuals. (Adams et al., Principles of Neurology, 6th ed, p686) [MeSH]

MedDRA Code

10074943

MeSH ID

D020362

ADR Severity Grade (FAERS)

ADR Severity Grade (CTCAE)

Not Available

Synonym

Paraneoplastic cerebellar degeneration | Secondary cerebellar degeneration | Paraneoplastic Cerebellar Degeneration | Degeneration, Paraneoplastic Cerebellar | Cerebellar Syndrome, Paraneoplastic | Cerebellar Syndromes, Paraneoplastic | Paraneoplastic Cerebellar Syndromes | Paraneoplastic Cerebellar Syndrome | Cerebellar Degeneration, Paraneoplastic | Paraneoplastic Cerebellar Degeneration, Anti-Yo-Associated | Paraneoplastic Cerebellar Degeneration, Anti Yo Associated | Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration | Anti Yo Associated Paraneoplastic Cerebellar Degeneration

Drugs Leading to the ADR

Drug ID	Drug Name	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)
BADD_D02248	Topotecan	0.000112%
The 1th Page 1 Total 1 Pages